European Archives - Page 60 of 986 - European Medical Journal

Rising Immunotherapy Use in Kidney and Bladder Cancer Highlights Disparities

Recent analysis from the National Cancer Database (NCDB) reveals a significant uptick in immunotherapy (IO) use for advanced kidney and bladder cancers….

Rifaximin Beats Lactulose in Preventing Hepatic Encephalopathy Recurrence: ACG 2024

Research presented at the American College of Gastroenterology (ACG) 2024 Annual Meeting showed that rifaximin monotherapy significantly reduces the risk of recurring overt hepatic encephalopathy

GLP-1 Drugs for Type 2 Diabetes Reduce Pancreatic Cancer Risk: ACG 2024

New research presented at the American College of Gastroenterology (ACG) Annual Meeting suggests that GLP-1 receptor agonists (GLP-1RAs) may significantly lower the risk of pancreatic cancer in patients with type 2 diabetes

Warning Issued as Scabies Cases Surge Across England

The Royal College of General Practitioners (RCGP) has reported a significant rise in scabies cases presenting at GP surgeries across England…

Long-Term Effects of Recurrent Rejection on Paediatric Heart Transplant Outcomes

Analysis of recurrent rejection (RR) in paediatric heart transplant recipients revealed that 17% of the population studied experienced RR.

24-Hour Antibiotic Course Prevents Infection Post-Cystectomy

A recent single-centre, randomised, trial has explored the effects of a 24-hour perioperative antibiotic course for patients undergoing cystectomy.

Air Pollution's Role in Rising Global Asthma Cases

Recent studies and meta-analyses have investigated the impact of PM2.5 on asthma, yet findings remain inconsistent.

AI Model Matches Radiologists in Detecting Chest X-Ray Abnormalities

A commercially available AI model has been found to perform on par with radiologists in detecting chest X-ray abnormalities.

Semaglutide Reduces Risk of Alzheimer’s Disease

Compared to other anti-diabetic drugs, semaglutide, also known as Ozempic, may lower the risk of Alzheimer’s disease in people with Type 2 diabetes (T2D).

5 stars

Boehringer, Amgen and Novartis rank top for cardiovascular patient groups

Boehringer Ingelheim, Amgen and Novartis have been awarded the highest reputation scores by several cardiovascular patient advocacy groups.